Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

• Үндсэн зохиолчид: Lin Fan (Зохиогч), Yuanyuan Zhang (Зохиогч), Peter Maguire (Зохиогч), Dominic Muston (Зохиогч), Matthew Monberg (Зохиогч), Jagadeswara Rao Earla (Зохиогч), Adela Mihai (Зохиогч), Poonam Gulati (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background The economic impact of adverse events (AEs) for poly (ADP-ribose) polymerase inhibitors (PARPis) in ovarian or breast cancer has not been widely evaluated.Objective Compare PARPi-related AE management costs from a US payer perspective.Methods The frequency of treatment-related grade 3-4 A...